logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
C

Coriolan Lebreton

Medical Oncology Department
H指数:3
被引数:40

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association between molecular classification and overall survival in patients with metastatic endometrial carcinoma: ancillary results of the UTOLA phase II GINECO trial.

转移性子宫内膜癌患者中分子分型与总生存期的关联：UTOLA II期GINECO试验的辅助结果。

International Journal of Gynecological Cancer
IF4.7
2025-11-210
PRE
Guillaume Beinse; Karen Leroy; Pierre-Alexandre Just; Corinne Jeanne; François Cherifi; Alexandra Leary; Olivia Le Saux; Benoît You; Manuel Rodrigues; Laurence Gladieff; Sophie Abadie-Lacourtoisie; Leïla Bengrine Lefevre; Pierre-Emmanuel Brachet; Coriolan Lebreton; Guillaume Meynard; Pierre Fournel; Jean-Sébastien Frenel; Frédéric Selle; Rémy Largillier; Cyril Foa
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial

奥拉帕利维持治疗在铂类为基础化疗后的晚期/转移性子宫内膜癌中的应用：GINECO随机IIb期UTOLA试验

Nature Communications
IF15.7
2025-08-260
OAAI
Florence Joly; Alexandra Leary; Isabelle Ray-Coquard; Bernard Asselain; Manuel Rodrigues; Laurence Gladieff; Guillaume Meynard; Sophie Abadie-Lacourtoisie; Coriolan Lebreton; Leïla Bengrine Lefevre; Pierre Fournel; Rémy Largillier; Frédéric Selle; Jean-Sébastian Frenel; Yolanda Fernandez Diez; Cyril Foa; Philippe Follana; Jérôme Meunier; Michel Fabbro; Anne-Claire Hardy Bessard; Isabelle Cojean-Zelek; Emilie Kaczmarek; Elise Bonnet; Antoine Arnaud; Sophie Roche; Karen Leroy; Pierre-Alexandre Just; Raphaël Leman; Corinne Jeanne; Céline Callens; Benoit You; Jérôme Alexandre
Phase II study of efficacy and safety of palbociclib in patients with recurrent ovarian cancer

帕博西利（palbociclib）在复发性卵巢癌患者中的有效性和安全性II期研究

International Journal of Gynecological Cancer
IF4.7
2025-07-280
OAAI
Gottfried E. Konecny; Tara M. Davidson; Coriolan L. Lebreton; Leah A. Marsh; Deandra K. Chetram; Hunter J. Atkinson; Melissa C. Larson; Ann L. Oberg; Nabilah Abdelaal; Jordyn Silverstein; Aminah Jatoi; Anita Washburn; Jill Burton; Sean Dowdy; Liying Zhang; Dorothy Hallberg; Victor E. Velculescu; Dennis J. Slamon; Andrea E. Wahner-Hendrickson
Prognostic Value of a Joint K-PD Model With Tumor Size Dynamics and CA-125 Kinetics in Recurrent Ovarian Cancer Patients: BOLD Phase II GINECO Study

复发卵巢癌患者中结合肿瘤大小动态和CA-125动力学的一种联合K-PD模型的预后价值：BOLD二期GINECO研究

cpt pharmacometrics systems pharmacology
IF0
2025-07-070
OA
Aurore Carrot; Pauline Corbaux; Olivier Colomban; Coriolan Lebreton; Laurence Gladieff; Olivier Tredan; Frédéric Selle; Cyril Abdeddaim; Alexandra Leary
NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer

NSGO-FANDANGO/ENGOT-EN1：一项关于在晚期/复发性子宫内膜癌中使用尼达尼布/安慰剂联合一线化疗的随机Ⅱ期研究

gynecologic oncology
IF4.1
2025-06-300
PRE
Kristina Lindemann; Dominique Berton; Jalid Sehouli; René DePont Christensen; Sevilay Altintas; Anja Ør Knudsen; Pierre-Etienne Heudel; Beyhan Ataseven; Ignace Vergote; Gabriel Lindahl; Coriolan Lebreton; Fabienne Schochter; Annika Auranen; Philippe Follana; Kristine Madsen; Frédéric Selle; Karen Stampe Petersson; Florence Joly; Elena Ioana Braicu; Mansoor Raza Mirza
Deep Learning Can Accurately Predict the Prognosis of Gynecologic Smooth Muscle Tumors of Uncertain Malignant Potential: A Multicenter Pilot Study

深度学习能够准确预测妇科平滑肌肿瘤不确定恶性潜能的预后：一项多中心试点研究

Laboratory Investigation
IF4.2
2025-06-300
PRE
João Costa; Van-Linh Le; Antonio De Leo; Caterina Ravaioli; Valérie Velasco; Ben Davidson; Tone Skeie-Jensen; Mojgan Devouassoux-Shisheboran; Alexis Trecourt; Carla Bartosch; Elisabete Rios; Catherine Genestie; Patricia Pautier; Coriolan Lebreton; Frédéric Guyon; Guillaume Babin; Jean-Michel Coindre; Francois Le Loarer; Olivier Saut; Sabrina Croce
PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network

PARP抑制剂在铂敏感复发性卵巢癌中的维持治疗：来自Unicancer网络的现实世界经验

ONCOLOGIST
IF4.2
2025-05-110
OA
Rippstein, Nicolas; Zemmour, Christophe; Rodrigues, Manuel; Ray-Coquard, Isabelle; Gladieff, Laurence; Pautier, Patricia; Frenel, Jean-Sebastien; Costaz, Helene; Lebreton, Coriolan; Pomel, Christophe; Colombo, Pierre-Emmanuel; Marchal, Frederic; Guillemet, Cecile; Rouge, Thibault de la Motte; Eberst, Lauriane; Bosquet, Lise; Deluche, Elise; Sabatier, Renaud
Exposure-response relationship of niraparib in maintenance therapy for recurrent ovarian cancer: ancillary analysis of the French GINECO-NiQoLe study

尼拉帕利在复发性卵巢癌维持治疗中的暴露-反应关系：法国GINECO-NiQoLe研究的附加分析

ESMO OPEN
IF8.3
2025-05-010
PRE
Quesada, S.; Puszkiel, A.; Jouinot, A.; Thomas, R.; Kalbacher, E.; Follana, P.; Hardy-Bessard, A. -c.; Brachet, P. -e.; Combe, P.; Selle, F.; Lebreton, C.; Fournel, P.; Mille, D.; Alexandre, J.; Grellety, T.; Emambux, S.; Le Roux, D.; Spaeth, D.; Fabbro, M.; Joly, F.; Blanchet, B.
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ ENGOT-ov25 trial

在完成奥拉帕利一线维持治疗后复发的晚期卵巢癌患者中后续治疗的有效性：PAOLA-1/ENGOT-ov25试验的结果

ANNALS OF ONCOLOGY
IF65.4
2025-02-012
OAAI
Harter, P.; Marth, C.; Mouret-Reynier, M. -A.; Cropet, C.; Lorusso, D.; Guerra-Alia, E. M.; Matsumoto, T.; Vergote, I.; Colombo, N.; Maenpaa, J.; Lebreton, C.; de Gregorio, N.; Mosconi, A. M.; Rubio-Perez, M. J.; Bourgeois, H.; Fasching, P. A.; Cecere, S. C.; Hardy-Bessard, A. C.; Denschlag, D.; de Percin, S.; Hanker, L.; Favier, L.; Bauerschlag, D.; Desauw, C.; Hillemanns, P.; Largillier, R.; Sehouli, J.; Grenier, J.; Pujade-Lauraine, E.; Ray-Coquard, I.
Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial

晚期上皮性卵巢癌患者中，诊断时循环肿瘤DNA的预后价值及其在完成一周期新辅助化疗后的早期下降情况。一项CHIVA II期GINECO试验的辅助分析。

gynecologic oncology
IF4.1
2025-01-010
OAAI
Azais, Henri; Brochard, Camille; Taly, Valerie; Benoit, Louise; Ferron, Gwenael; Ray-Coquard, Isabelle; You, Benoit; Abadie-Lacourtoisie, Sophie; Lebreton, Coriolan; Venat, Laurence; Louvet, Christophe; Favier, Laure; Blonz, Cyriac; Dohollou, Nadine; Malaurie, Emmanuelle; Dubot, Coraline; Kurtz, Jean-Emmanuel; Pujade-Lauraine, Eric; Rouleau, Etienne; Leary, Alexandra; Bats, Anne-Sophie; Blons, Helene; Laurent-Puig, Pierre
Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe)
JNCI CANCER SPECTRUM
IF4.1
2024-12-141
OAAI
Joly, Florence; Bazan, Fernando; Garbay, Delphine; Ouldbey, Yaelle; Follana, Philippe; Champeaux-Orange, Elise; Legouffe, Eric; Brachet, Pierre-Emmanuel; Spaeth, Dominique; Combe, Pierre; Hardy-Bessard, Anne-Claire; Selle, Frederic; Grenier, Julien; Lebreton, Coriolan; Derbel, Olfa; Bonnet, Elise; Fournel, Pierre; Diez, Yolanda Fernandez; Delecroix, Valerie; Emambux, Sheik; Alexandre, Jerome; Grellety, Thomas; Mille, Dominique; Orfeuvre, Hubert; Favier, Catherine; Le Roux, Delphine; Mouret-Reynier, Marie-Ange; Quesada, Stanislas; Kurtz, Jean-Emmanuel
FcgR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 (avelumab) in gestational trophoblastic neoplasia

FcgR3A多态性影响自然杀伤细胞活化以及对PD-L1抗体（avelumab）的应答反应在妊娠滋养层肿瘤中

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
IF8.4
2024-10-010
OAAI
Msika, A; Mathias, V; Boudigou, M; Chambon, M; Dubois, V; Hajri, T; Lotz, JP; Massardier, J; Descargues, P; Gladieff, L; Joly, F; Lebreton, C; Maucort-Boulch, D; Bin, SY; Rousset, P; Allias, F; Gaillot-Durand, L; Devouassoux-Shisheboran, M; Lemaitre, N; Alfaidy, N; Langlois-Jacques, C; Alves-Ferreira, M; Golfier, F; You, BN; Thaunat, O; Bolze, PA; Koenig, A
Role of tumor primary chemosensitivity assessed by modeled CA-125 KELIM to predict complete interval debulking surgery (IDS) in ovarian carcinoma patients treated with neo-adjuvant chemotherapy and immunotherapy: A GINEGEPS/GINECO study of the NeoPembrOv and INeOV trials

通过模拟CA-125 KELIM评估肿瘤原发性化疗敏感性，以预测接受新辅助化疗和免疫治疗治疗的卵巢癌患者完全间隔减瘤术（IDS）的作用：一项GINEGEPS/GINECO研究，来自NeoPembrOv和INeOV试验

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Corbaux, P.; Leary, A.; Le Saux, O.; Colomban, O.; Treilleux, I.; Genestie, C.; Chardin, L.; Collet, L.; Lefevre, L. Bengrine; Kuentz, M. Auvray; Martinez, M.; Blonz, C.; Priou, F.; Alexandre, J.; Cloarec, N.; Lebreton, C.; Venat, L.; Savoye, A. M.; You, B.; Ray-Coquard, I. L.
Avelumab plus methotrexate to eradicate low-risk gestational trophoblastic tumors in first-line setting: TROPHAMET phase I/II trial

阿维鲁姆单抗联合甲氨蝶呤在一线治疗中根除低危妊娠滋养细胞肿瘤：TROPHAMET I/II期试验

ANNALS OF ONCOLOGY
IF65.4
2024-09-011
PRE
You, B.; Lotz, J-P.; Descargues, P.; Lobbedez, F. Joly; Rouge, T. De La Motte; Lebreton, C.; Gladieff, L.; Follana, P.; Jamelot, M.; Massardier, J.; Hajri, T.; Alves-Ferreira, M.; Bin, S.; Langlois-Jacques, C.; Bonjour, M.; Roux, A.; Desauw, C.; Gross, M. Provansal; Golfier, F.; Bolze, P-A.
Validation of circulating tumor DNA for prognostication and monitoring in metastatic endometrial carcinoma: Ancillary results from the phase II randomized GINECO trial UTOLA

循环肿瘤DNA在转移性子宫内膜癌预后判断和监测中的验证：GINECO试验UTOLA II期随机研究的附加结果

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Beinse, G.; Taly, V.; Leary, A.; Baures, A.; Tredan, O.; You, B.; Rodrigues, M. J.; Gladieff, L.; Lacourtoisie, S. Abadie; Lefevre, L. Bengrine; Brachet, P-E.; Lebreton, C.; Kalbacher, E.; Fournel, P.; Frenel, J-S.; Selle, F.; Largillier, R.; Laurent-Puig, P.; Lobbedez, F. Joly; Alexandre, J.
Initial management and long-term outcome of ovarian clear cell carcinoma (OCCC) in the French multicentre ESME database

法国多中心ESME数据库中卵巢透明细胞癌(OCCC)的初始管理和长期预后

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Zenatri, M.; Martin, E.; Rodrigues, M. J.; Ray-Coquard, I. L.; Gladieff, L.; Colombo, P-E.; Sabatier, R.; Lobbedez, F. Joly; Rouge, T. De La Motte; Pomel, C.; Guillemet, C.; Petit, T.; Fumet, J-D.; Lebreton, C.; Rossi, L.; Pautier, P.; Follana, P.; Bosquet, L.; Frenel, J-S.; Augereau, P.
Safety and tolerability of durvalumab (D) plus carboplatin/paclitaxel (CP) plus bevacizumab (B) followed by D, B plus olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial

在DUO-O III期试验中，评估 durvalumab (D) 联合 carboplatin/paclitaxel (CP) 及 bevacizumab (B) 诱导治疗后，再给予 D、B 联合 olaparib (O) 维持治疗（mtx）在无肿瘤 BRCA1/BRCA2 突变（non-tBRCAm）的新诊断晚期卵巢癌（AOC）患者中的安全性与耐受性。

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Aghajanian, C.; Schmalfeldt, B.; Okamoto, A.; Reuss, A.; Kim, J-W.; Ospina, G. Marquina; Ayhan, A.; Salutari, V.; Lebreton, C.; Labudovic, D.; Tognon, G.; Chudecka-Glaz, A. M.; Berger, R.; Lheureux, S.; Henry, S.; Burges, A.; Wenham, R. M.; Nishio, S.; Marshall, L.; Harter, P.
TEDOVA: vaccine OSE2101+/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer

TEDOVA: 疫苗OSE2101 /- pembrolizumab作为铂敏感复发性卵巢癌的维持

FUTURE ONCOLOGY
IF2.6
2024-08-190
PRE
Kabirian, Rayan; Tredan, Olivier; Marme, Frederik; Paoletti, Xavier; Eberst, Lauriane; Lebreton, Coriolan; Rouge, Thibault De La Motte; Sabatier, Renaud; Angelergues, Antoine; Fabbro, Michel; Van Gorp, Toon; Mansi, Laura; Gladieff, Laurence; Kaczmarek, Emilie; Alexandre, Jerome; Grellety, Thomas; Favier, Laure; Welz, Julia; Frenel, Jean-Sebastien; Leary, Alexandra
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
LANCET
IF88.5
2024-01-0155
OAAI
Oaknin, Ana; Gladieff, Laurence; Martinez-Garcia, Jeronimo; Villacampa, Guillermo; Takekuma, Munetaka; De Giorgi, Ugo; Lindemann, Kristina; Woelber, Linn; Colombo, Nicoletta; Duska, Linda; Leary, Alexandra; Godoy-Ortiz, Ana; Nishio, Shin; Angelergues, Antoine; Rubio, Maria Jesus; Farinas-Madrid, Lorena; Yamaguchi, Satoshi; Lorusso, Domenica; Ray-Coquard, Isabelle; Manso, Luis; Joly, Florence; Alarcon, Jesus; Follana, Philippe; Romero, Ignacio; Lebreton, Coriolan; Perez-Fidalgo, J. Alejandro; Yunokawa, Mayu; Dahlstrand, Hanna; D'Hondt, Veronique; Randall, Leslie

研究方向

暂未获取到该数据
A
Alexandra Léary
H 指数:62论文数:715被引数:2.4万
L
Laurence Gladieff
H 指数:43论文数:347被引数:9,731
F
Frédèric Selle
H 指数:40论文数:296被引数:1.4万
P
Philippe Follana
H 指数:30论文数:246被引数:6,977
J
Jean‐Sébastien Frenel
H 指数:38论文数:411被引数:8,244
B
Benoît You
H 指数:47论文数:547被引数:1.1万
P
P. Fournel
H 指数:35论文数:328被引数:9,469
J
Jérôme Alexandre
H 指数:29论文数:269被引数:3,706
M
Manuel Rodrigues
H 指数:33论文数:368被引数:8,586
L
L. Bengrine Lefevre
H 指数:8论文数:54被引数:223